Biogen is looking to improve the standard of care in spinal muscular atrophy with an aggressive development plan for Spinraza (nusinersen) follow-on salanersen (BIIB115), presenting Phase I data on June 25 at the SMA Research and Clinical Care meeting and outlining its goal to proceed directly from Phase I to a registrational Phase III program.
Key Takeaways
- Biogen’s Phase I data for Spinraza follow-on salanersen shows ability to restore functioning SMN protein and reduce neurofilament levels, which may provide a disease-modifying effect.
Like Spinraza, salanersen is also an antisense oligonucleotide (ASO) therapy licensed from Ionis that acts to normalize production of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?